GlassScriptPhysician profile
Jeffrey A Thomas
NPI 1811935778
$14,328.96
in general payments reported to CMS, 2019-2025
69 companies · $2,723 in 2025
The $2,723 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,508 · 2020: $774 · 2021: $2,608 · 2022: $2,020 · 2023: $2,317 · 2024: $2,380 · 2025: $2,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,316 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,315.61 |
| Education | $104.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,050.21 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,018.33 | 2019-2025 | |
| Pfizer INC. | $627.24 | 2019-2025 | |
| Abbvie INC. | $620.16 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $611.09 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $606.23 | 2020-2025 | Enhertu |
| Genentech USA, INC. | $568.27 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Seagen INC. | $546.84 | 2019-2025 | Adcetris, Padcev, Tukysa |
| Genzyme Corporation | $510.33 | 2019-2025 | |
| Incyte Corporation | $493.47 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $433.56 | 2019-2025 | Darzalex, Talvey, Erleada |
| Gilead Sciences, INC. | $428.57 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $425.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $423.91 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Celgene Corporation | $403.76 | 2022-2025 | Reblozyl, Pomalyst |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $385.34 | 2019-2025 | Cabometyx |
| Eisai INC. | $346.55 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $339.64 | 2019-2023 | Imbruvica |
| Amgen INC. | $293.54 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Stemline Therapeutics INC. | $285.47 | 2023-2025 | Orserdu, Elzonris |
| Jazz Pharmaceuticals INC. | $261.87 | 2021-2025 | Zepzelca |
| Lilly USA, LLC | $224.02 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $216.07 | 2019-2025 | Iclusig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $204.75 | 2019-2024 | Libtayo |
| Rigel Pharmaceuticals, INC. | $176.83 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Adaptive Biotechnologies Corporation | $169.68 | 2022-2025 | Clonoseq |
| Karyopharm Therapeutics INC. | $166.26 | 2020-2024 | Xpovio |
| Epizyme, INC. | $156.30 | 2021-2022 | |
| Beigene USA, INC. | $150.24 | 2021-2024 | Brukinsa |
| Pharmaessentia USA Corporation | $142.03 | 2024-2025 | Besremi |
| Puma Biotechnology, INC. | $139.84 | 2021-2025 | Nerlynx |
| Array Biopharma INC | $138.00 | 2019-2025 | Braftovi, Tukysa, Mektovi |
| Ipsen Biopharmaceuticals, INC | $122.30 | 2019-2024 | Onivyde, Tazverik |
| Octapharma USA, INC. | $116.66 | 2020 | |
| Deciphera Pharmaceuticals INC. | $109.60 | 2021-2025 | Qinlock, Romvimza |
| Clovis Oncology, INC. | $106.57 | 2020 | |
| Blueprint Medicines Corporation | $94.23 | 2021-2025 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $88.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.64 | 2020-2024 | Opdualag |
| Tersera Therapeutics LLC | $78.20 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $73.69 | 2021-2024 | |
| Coherus Oncology, INC. | $70.52 | 2021-2023 | |
| Sobi, INC | $66.78 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $56.58 | 2022-2025 | Ultomiris |
| Taiho Oncology, INC. | $53.92 | 2023-2025 | |
| Kite Pharma, INC. | $53.29 | 2022-2025 | Yescarta |
| Tesaro, INC. | $51.58 | 2019 | |
| Astellas Pharma US INC | $43.83 | 2021-2023 | |
| Verastem, INC. | $41.56 | 2019 | |
| Beone Medicines USA, INC. | $40.85 | 2025 | Tevimbra |
| Cti Biopharma Corp. | $39.54 | 2023 | Vonjo |
| Morphosys, US INC. | $39.23 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.99 | 2019-2021 | |
| Mirati Therapeutics, INC. | $36.82 | 2024 | Krazati |
| Genmab U.S., INC. | $32.40 | 2024 | Epkinly |
| Dendreon Pharmaceuticals LLC | $26.14 | 2025 | Provenge |
| Acrotech Biopharma INC. | $22.91 | 2024 | Beleodaq |
| Corcept Therapeutics | $21.10 | 2025 | Korlym |
| Geron Corporation | $19.61 | 2025 | Rytelo |
| Legend Biotech USA INC. | $18.61 | 2024 | |
| Adc Therapeutics America, INC. | $18.13 | 2024 | |
| Accord Healthcare, INC. | $15.20 | 2025 | |
| Foundation Medicine, INC. | $14.46 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.51 | 2024 | Myrisk |
| Spectrum Pharmaceuticals INC. | $13.25 | 2023 | Rolvedon |
| Acceleron Pharma, INC. | $13.07 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.07 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.94 | 2019 | |
| Emd Serono, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.